trospium   Click here for help

GtoPdb Ligand ID: 7480

Synonyms: Flotros® | IP-631 | IP631 | Regurin® | Sanctura®
Approved drug
trospium is an approved drug (FDA (2004))
Compound class: Synthetic organic
Comment: The marketed product contains trospium chloride (PubChem CID 107979). Note that the INN record for trospium chloride represents a chiral molecule, the closest PubChem match being AC1NR4SW. Our representation and those contained in our links show the non-isomeric molecule.
Trospium is a peripherally restricted muscarinic receptor antagonist.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 46.53
Molecular weight 392.22
XLogP 4.04
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(C(c1ccccc1)(c1ccccc1)O)OC1CC2CCC(C1)[N+]12CCCC1
Isomeric SMILES O=C(C(c1ccccc1)(c1ccccc1)O)OC1CC2CCC(C1)[N+]12CCCC1
InChI InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1
InChI Key OYYDSUSKLWTMMQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Trospium chloride is a muscarinic antagonist used clinically as a urinary antispasmodic, indicated for the treatment of overactive bladder syndrome.
An oral dual-drug fixed-dose combination of the M1/M4 receptor agonist xanomeline and trospium (known as KarXT™) is proposed as as novel schizophrenia therapy [1,3].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Trospium chloride is a muscarinic antagonist [2]. The parasympatholytic action of trospium chloride, induces relaxation of the detrusor muscle in the wall of the bladder and reduces over all muscle tone in the bladder, thereby increasing volume and decreasing the symptoms of urge incontinence, urgency, and urinary frequency associated with overactive bladder syndrome.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03697252 A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia Phase 2 Interventional Karuna Therapeutics
NCT04659161 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) Phase 3 Interventional Karuna Therapeutics
External links Click here for help